Log in

LON:IMMImmuPharma Share Price, Forecast & News

GBX 15.50
+0.12 (+0.78 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: GBX 15.50
50-Day Range
MA: GBX 14.80
52-Week Range
Now: GBX 15.50
Volume1.12 million shs
Average Volume817,845 shs
Market Capitalization£28.37 million
P/E RatioN/A
Dividend YieldN/A
ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which has completed Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists; and the development of peptides as glucagon antagonists to treat type I and type II diabetes; and a clinical development collaboration agreement with Incanthera Limited for Nucant cancer programme. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Read More
ImmuPharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.75 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual Sales£77,925.00
Cash FlowGBX 0.77 per share
Book ValueGBX 3.10 per share



Market Cap£28.37 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMM News and Ratings via Email

Sign-up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.

ImmuPharma (LON:IMM) Frequently Asked Questions

How has ImmuPharma's stock been impacted by COVID-19 (Coronavirus)?

ImmuPharma's stock was trading at GBX 10.76 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IMM shares have increased by 44.1% and is now trading at GBX 15.50. View which stocks have been most impacted by Coronavirus.

How were ImmuPharma's earnings last quarter?

ImmuPharma PLC (LON:IMM) released its quarterly earnings results on Thursday, April, 30th. The company reported ($3.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.90) by $1.09. View ImmuPharma's earnings history.

Has ImmuPharma been receiving favorable news coverage?

Media coverage about IMM stock has been trending positive on Saturday, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ImmuPharma earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutImmuPharma.

Who are some of ImmuPharma's key competitors?

What other stocks do shareholders of ImmuPharma own?

Who are ImmuPharma's key executives?

ImmuPharma's management team includes the following people:
  • Mr. Dimitri F. Dimitriou, Co-Founder, CEO & Director (Age 57)
  • Dr. D. Robert Henri Zimmer M.D., Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 71)
  • Ms. Tracy Weimar BA, MBA, VP of Operations & Fin. and Company Sec.
  • Dr. Jean-Marie Geiger PharmD, MD, Head of Clinical Devel.

What is ImmuPharma's stock symbol?

ImmuPharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."

How do I buy shares of ImmuPharma?

Shares of IMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ImmuPharma's stock price today?

One share of IMM stock can currently be purchased for approximately GBX 15.50.

How big of a company is ImmuPharma?

ImmuPharma has a market capitalization of £28.37 million and generates £77,925.00 in revenue each year. ImmuPharma employs 10 workers across the globe.

What is ImmuPharma's official website?

The official website for ImmuPharma is www.immupharma.org.

How can I contact ImmuPharma?

ImmuPharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The company can be reached via phone at +44-20-71524080.

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.